Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure-Reference-Cited by-同舟云学术

Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure

Published:2001-08 Issue:4 Volume:3 Page:457-461
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European Journal of Heart Failure

Author:

Gad Cotter¹,Wolfgang Kiowski²,Edo Kaluski¹,Isaac Kobrin³,Olga Milovanov¹,Alon Marmor⁴,Jamal Jafari⁵,Leonardo Reisin⁵,Ricardo Krakover¹,Zvi Vered¹,Avi Caspi⁶

Affiliation:

1. The Cardiology Institute; Assaf-Harofeh Medical Center; 70300 Zerifin Israel

2. The Division of Cardiology; University Hospital; Zurich Switzerland

3. Actelion Ltd; Allschwil Switzerland

4. Rebecca Sieff Government Hospital; Safed Israel

5. Ashkelon Hospital; Ashkelon Israel

6. Kaplan Hospital; Kaplan Israel

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.